RxSight Q1 revenue beats estimates

RxSight

06/05/2026 21:53

Overview

Ophthalmic device maker's Q1 revenue fell 18.5% yr/yr but beat analyst expectations

Adjusted EPS for Q1 beat consensus despite wider net loss yr/yr

Gross margin rose due to favorable shift in product mix toward LAL sales

Outlook

RxSight sees 2026 revenue of $120 mln to $135 mln, unchanged from prior guidance

Company expects 2026 gross margin of 70% to 72%, unchanged from prior guidance

Operating expenses for 2026 expected at high end of $150 mln to $160 mln range

Result Drivers

LOWER LDD VOLUMES - Co said Q1 revenue decline was largely due to lower Light Delivery Device unit volumes

PRODUCT MIX SHIFT - Gross margin improvement attributed to a favorable shift in product mix toward LAL sales

HIGHER OPERATING EXPENSES - Operating expenses rose due to continued expansion of global commercial and support teams

Company press release: ID:nGNX699MgV

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$30.90 mln
$29.74 mln (9 Analysts)
Q1 Adjusted EPS
Beat
-$0.19
-$0.28 (9 Analysts)
Q1 EPS
-$0.38


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 7 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Rxsight Inc is $9.00, about 24% above its May 5 closing price of $7.26

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)